Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Merck & Co., Inc. — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $48.01, while Merck & Co., Inc. trades at $123.43 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | MRK | |
|---|---|---|
52-Week High | $49.91 | $129.52 |
52-Week Low | $47.57 | $77.60 |
Market Cap | — | $298.31B |
Sector | — | Health |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.
Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.
Merck (MRK) trades at $123.45, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, including Q1 2026, and the company is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Revenue reached $65.01B in 2025 with a net income margin of 28.07%, though 2026 forecasts show a decline in profitability.
The outlook remains positive with a consensus price target of $137.30, offering ~11% upside. Key risks include increased debt levels, competitive pressures in oncology, and potential regulatory hurdles from acquisitions. Institutional buying activity supports confidence, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
